Regulatory T cells in obesity: the leptin connection

Trends in Molecular Medicine

Volumn 16, Issue 6, 2010, Pages 247-256

  Matarese, Giuseppe ^a   Procaccini, Claudio ^a   De Rosa, Veronica ^a   Horvath, Tamas L ^b   La Cava, Antonio ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; DRUG MECHANISM; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INSULIN RESISTANCE; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; OBESITY; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; HUMANS; LEPTIN; MODELS, BIOLOGICAL; OBESITY; T-LYMPHOCYTES, REGULATORY;

EID: 77953477314     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.04.002     Document Type: Review

References (116)

1. O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature 19 (2009) 307-314
2. Friedman J.M. Obesity: causes and control of excess body fat. Nature 21 (2009) 340-342
3. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 14 (2006) 860-867
4. Bastard J.P., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 (2006) 4-12
5. La Cava A., et al. The weight of leptin in immunity. Nat. Rev. Immunol. 4 (2004) 371-379
6. Zhang Y., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
7. Tartaglia L.A., et al. Identification and expression cloning of a leptin receptor, Ob-R. Cell 83 (1995) 1263-1270
8. Montague C.T., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 (1997) 903-908
9. Clément K., et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 (1998) 398-401
10. Krude H., et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet. 19 (1998) 155-157
11. Jackson R.S., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat. Genet. 16 (1997) 303-306
12. Vaisse C., et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 20 (1998) 113-114
13. Yeo G.S., et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat. Genet. 20 (1998) 111-112
14. Holder J.L., et al. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum. Mol. Genet. 9 (2000) 101-108
15. Bochukova E.G., et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature 463 (2010) 666-670
16. Matarese G., et al. The intricate interface between immune system and metabolism. Trends Immunol. 25 (2004) 193-200
17. Matarese G., et al. Balancing susceptibility to infection and autoimmunity: a role for leptin?. Trends Immunol. 23 (2002) 182-187
18. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
19. Wing K., et al. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11 (2009) 7-13
20. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
21. Hori S., et al. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
22. Fontenot J.D., et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003) 330-336
23. Shevach E.M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity. 30 (2009) 636-645
24. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2 (2002) 389-400
25. Sakaguchi S., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182 (2001) 18-32
26. Stephens G.L., et al. Foxp3+ regulatory T cells: selfishness under scrutiny. Immunity. 27 (2007) 417-419
27. Petrausch U., et al. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr. Mol. Med. 9 (2009) 673-682
28. Wildin R.S., et al. IPEX and FOXP3: clinical and research perspectives. J. Autoimmun. 25 (2005) 56-62
29. Bennett C.L., et al. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr. 13 (2001) 533-538
30. Friedman J.M., et al. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
31. Garfield A.S., et al. Role of central melanocortin pathways in energy homeostasis. Trends Endocrinol. Metab. 20 (2009) 203-215
32. Gao Q., et al. Neuronal control of energy homeostasis. FEBS Lett. 9 (2008) 132-141
33. Dietrich M.O., et al. Feeding signals and brain circuitry. Eur. J. Neurosci. 30 (2009) 1688-1696
34. Horvath T.L., et al. Developmental programming of the hypothalamus: a matter of fat. Nat. Med. 12 (2006) 52-53
35. Abizaid A., et al. Thoughts for food: brain mechanisms and peripheral energy balance. Neuron. 21 (2006) 691-702
36. Horvath T.L. The hardship of obesity: a soft-wired hypothalamus. Nat. Neurosci. 8 (2005) 561-565
37. Andrews Z.B., et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 14 (2008) 846-851
38. Gropp E., et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat. Neurosci. 8 (2005) 1289-1291
39. Jenks B.G. Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved. Ann. N. Y. Acad. Sci. 1163 (2009) 17-30
40. Santini F., et al. Melanocortin-4 receptor mutations in obesity. Adv. Clin. Chem. 48 (2009) 95-109
41. Symonds M.E., et al. Nutritional programming of the metabolic syndrome. Nat. Rev. Endocrinol. 5 (2009) 604-610
42. Maury E., et al. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell Endocrinol. 15 (2010) 1-16
43. Hotamisligil G.S., et al. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43 (1994) 1271-1278
44. Spiegelman B.M., et al. Through thick and thin: wasting, obesity, and TNF alpha. Cell 73 (1993) 625-627
45. Bullo M., et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 11 (2003) 525-531
46. Lumeng C.N., et al. T-ing up inflammation in fat. Nat. Med. 15 (2009) 846-847
47. Rasouli N., et al. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab. 93 (2008) 64-73
48. MacLaren R., et al. Adipokines and the immune system: an adipocentric view. Adv. Exp. Med. Biol. 632 (2008) 1-21
49. Dixit V.D. Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J. Leukoc. Biol. 84 (2008) 882-892
50. Bilan P.J., et al. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch. Physiol. Biochem. 115 (2009) 176-190
51. Bourlier V., et al. Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab. 35 (2009) 251-260
52. Farooqi I.S., et al. Leptin: a pivotal regulator of human energy homeostasis. Am. J. Clin. Nutr. 89 (2009) 980-984
53. Munzberg H., et al. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 8 (2005) 566-570
54. Schwartz M.W., et al. Central nervous system control of food intake. Nature 404 (2000) 661-671
55. Banks W.A. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. Curr. Pharm. Des. 7 (2001) 125-133
56. Banks W.A., et al. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E10-15
57. Banks A.S., et al. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275 (2000) 14563-14572
58. Howard J.K., et al. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat. Med. 10 (2004) 734-738
59. Mori H., et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat. Med. 10 (2004) 739-743
60. Elchebly M., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283 (1999) 544-1548
61. Klaman L.D., et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell Biol. 20 (2000) 5479-5489
62. Rondinone C.M., et al. Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes. 51 (2002) 2405-2411
63. Munzberg H. Differential leptin access into the brain - a hierarchical organization of hypothalamic leptin target sites?. Physiol. Behav. 94 (2008) 664-669
64. Irani B.G., et al. Effects of leptin on rat ventromedial hypothalamic neurons. Endocrinology. 149 (2008) 5146-5154
65. Yang R., et al. c-Jun N-terminal kinase pathways in diabetes. Int. J. Biochem. Cell. Biol. 40 (2008) 2702-2706
66. Ruan H., et al. The adipocyte IKK/NFkappaB pathway: a therapeutic target for insulin resistance. Curr. Opin. Investig. Drugs. 10 (2009) 346-352
67. Kleinridders A., et al. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab. 10 (2009) 249-259
68. Wisse B.E., et al. Does hypothalamic inflammation cause obesity?. Cell Metab. 10 (2009) 241-242
69. Chang-Chen K.J., et al. Beta-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord. 9 (2008) 329-343
70. Robertson R.P. Beta-cell deterioration during diabetes: what's in the gun?. Trends Endocrinol. Metab. 20 (2009) 388-393
71. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β cells in diabetes. J. Biol. Chem. 279 (2004) 42351-42354
72. Evans J.L., et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23 (2002) 599-622
73. Eizirik D.L., et al. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29 (2008) 42-61
74. De Rosa V., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 26 (2007) 241-255
75. Matarese G., et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J. Immunol. 166 (2001) 5909-5916
76. Klingenberg, R. et al. (2010) Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. Feb 18
77. Nilsson J., et al. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. J. Intern. Med. 266 (2009) 221-231
78. Hansson G.K., et al. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin. Immunopathol. 31 (2009) 95-101
79. Dunér P., et al. Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease. J. Intern. Med. 265 (2009) 593-603
80. Wigren M., et al. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ. Res. 104 (2009) e62-70
81. Taleb S., et al. Regulatory T-cell immunity and its relevance to atherosclerosis. J. Intern. Med. 263 (2008) 489-499
82. Taleb S., et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2691-2698
83. Matarese G., et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5150-5155
84. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15 (2009) 930-939
85. Winer S., et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15 (2009) 921-929
86. Nishimura S., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15 (2009) 914-920
87. Liu J., et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 15 (2009) 940-945
88. Moro K., et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 463 (2009) 540-544
89. Sterry W., et al. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br. J. Dermatol 157 (2007) 649-655
90. Radetti G., et al. Thyroid function and structure are affected in childhood obesity. J. Clin. Endocrinol. Metab. 93 (2008) 4749-4754
91. Munger K.L., et al. Body size and risk of MS in two cohorts of US women. Neurology. 73 (2009) 1543-1550
92. Fessler M.B., et al. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr. Opin. Lipidol. 20 (2009) 379-385
93. Horvath T.L., et al. Fuel utilization by hypothalamic neurons: roles for ROS. Trends Endocrinol. Metab. 20 (2009) 78-87
94. Hotamisligil G.S. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. (Lond). 32 (2008) 52-54
95. Yang H., et al. Obesity accelerates thymic aging. Blood. 114 (2009) 3803-3812
96. Tanaka S., et al. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin. Endocrinol. 54 (2001) 347-354
97. Thomson A.W., et al. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9 (2009) 324-337
98. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 (2007) 1517-1526
99. Nath N., et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182 (2009) 8005-8014
100. Yang X., et al. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer?. Diabetologia. 50 (2007) 1127-1139
101. Hill M.J., et al. Obesity and diabetes: lipids, 'nowhere to run to'. Clin. Sci. (Lond) 116 (2009) 113-123
102. Jay M.A., et al. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes Rev. 3 (2007) 33-39
103. Klotz L., et al. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 206 (2009) 2079-2089
104. Zhang X., et al. Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol. Res. 41 (2008) 165-174
105. Sanchez-Margalet V., et al. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin. Exp. Immunol. 133 (2003) 11-19
106. Goren I., et al. Leptin and wound inflammation in diabetic ob/ob mice: differential regulation of neutrophil and macrophage influx and a potential role for the scab as a sink for inflammatory cells and mediators. Diabetes. 52 (2003) 2821-2832
107. Sánchez-Pozo C., et al. Leptin stimulates the oxidative burst in control monocytes but attenuates the oxidative burst in monocytes from HIV-infected patients. Clin. Exp. Immunol. 134 (2003) 464-469
108. Santos-Alvarez J., et al. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell. Immunol. 194 (1999) 6-11
109. Caldefie-Chezet F., et al. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action?. J. Leukoc. Biol. 69 (2001) 414-418
110. Zhao Y., et al. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem. Biophys Res. Commun. 300 (2003) 247-252
111. Tian Z., et al. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem. Biophys Res. Commun. 298 (2002) 297-302
112. Martín-Romero C., et al. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell. Immunol. 199 (2000) 15-24
113. Lord G.M., et al. Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J. Leukoc. Biol. 72 (2002) 330-338
114. Lord G.M., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (1998) 897-901
115. Howard J.K., et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest. 104 (1999) 1051-1059
116. Fujita Y., et al. Leptin inhibits stress-induced apoptosis of T lymphocytes. Clin. Exp. Immunol. 128 (2002) 21-26